Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Practice Management

COVID-19 Vaccines: AstraZeneca Resumes Trial; Pfizer, BioNTech Look to Expand Study

Diana Ernst, RPh

September 21, 2020

AstraZeneca has resumed a phase 3 clinical trial investigating AZD1222, its COVID-19 vaccine candidate.

General Rheumatology

Emergency Use Authorization Issued for COVID-19 Convalescent Plasma

Diana Ernst, RPh

August 26, 2020

The FDA has issued an Emergency Use Authorization (EUA) for the use of COVID-19 convalescent plasma.

Rheumatoid Arthritis

FDA Rejects Filgotinib NDA for Rheumatoid Arthritis

Diana Ernst, RPh

August 25, 2020

The FDA has issued a CRL to Gilead Sciences related to the NDA for filgotinib in the treatment of moderately to severely active rheumatoid arthritis.

patient having temperature checked, COVID19

Practice Management

Trial Investigating COVID-19 Therapy in Long-Term Care Facilities Begins

Diana Ernst, RPh

August 11, 2020

A phase 3 trial evaluating LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff of long-term care facilities has been initiated.

Practice Management

Phase 3 Trial of COVID-19 Vaccine Candidate mRNA-1273 Begins

Diana Ernst, RPh

July 31, 2020

Phase 3 trial initiated evaluating the vaccine candidate mRNA-1273 against COVID-19.

General Rheumatology

NIH: Trial Investigating Hydroxychloroquine for COVID-19 Stopped

Diana Ernst, RPh

June 25, 2020

A National Institutes of Health (NIH)-led clinical trial evaluating hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) has been halted after a data and safety monitoring board determined that the drug was unlikely to benefit hospitalized patients.

Practice Management

FDA: Coadministration of Remdesivir With Chloroquine or Hydroxychloroquine Not Recommended

Diana Ernst, RPh

June 18, 2020

The antiviral activity of remdesivir, an investigational treatment for COVID-19, may potentially be reduced if it is coadministered with chloroquine or hydroxychloroquine, according to the FDA.

Practice Management

FDA Revokes Emergency Use Authorization for Chloroquine, Hydroxychloroquine

Diana Ernst, RPh

June 17, 2020

The FDA has revoked the emergency use authorization for chloroquine phosphate and hydroxychloroquine sulfate based on emerging data suggesting that these agents are unlikely to be effective against COVID-19.

General Rheumatology

FDA: False Negatives Possible With Abbott’s Rapid COVID-19 Test

Diana Ernst, RPh

May 20, 2020

According to the Food and Drug Administration, the Abbott ID Now™ point-of-care test to diagnose coronavirus disease 2019 (COVID-19) may return false negative results based on early data.

General Rheumatology

NIH Trial Investigating Hydroxychloroquine Plus Azithromycin for COVID-19 Begins

Diana Ernst, RPh

May 18, 2020

The phase 2b trial is expected to include roughly 2000 participants with confirmed SARS-CoV-2 who are experiencing fever, cough, and/or shortness of breath.

Next post in General Rheumatology